NORD gratefully acknowledges Isabella Oliveira, NORD Editorial Intern from the Massachusetts College of Pharmacy and Health Sciences, and Prof. Dr. med. Benedict Schoser, Friedrich-Baur-Institute, Department of Neurology Klinikum München Ludwig-Maximilians-University Munich, Munich, Germany, for assistance in the preparation of this report.
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction. It is a miscommunication between the nerve cell and the muscles that lead to the gradual onset of muscle weakness. It starts in the proximal muscles of the legs or arms. LEMS can be categorized into two different classes: LEMS associated with small cell lung cancer (SCLC) and LEMS without cancer association. Approximately 60 percent of patients with LEMS have SCLC, and the onset of LEMS symptoms often precedes the detection of the cancer. LEMS patients with cancer tend to be older -predominantly males- and nearly always have a long history of smoking. In patients in which there is no associated cancer, disease onset can be at any age and are gender neutral. LEMS may impact quality of life depending on the severity of symptoms an individual presents with.
LEMS is characterized by weakness and fatigue especially of the muscles in the legs and arms. The disease may affect the patient’s ability to engage in strenuous exercise and may make such activities as climbing stairs or walking up a steep walkway difficult. Onset is gradual, typically taking place over several weeks to many months. There is often a progression of symptoms whereby the shoulder muscles, muscles of the feet & hands, speech & swallowing muscles and eye muscles are affected in a stepwise fashion. The symptoms progress more quickly when LEMS is associated with cancer. Most LEMS patients also exhibit the following symptoms (sometimes called autonomic symptoms): dry mouth, dry eyes, constipation, impotence, and decreased sweating. LEMS patients with or without cancer may also undergo significant weight loss. The tendon reflexes are diminished or absent on examination. Hence, in summary, LEMS is often described as a clinical “triad” of proximal muscle weakness, autonomic symptoms and reduced tendon reflexes.
LEMS is an autoimmune disorder. Autoimmune disorders are caused when the body’s natural defenses against “foreign” or invading organisms (e.g., antibodies) begin to attack healthy tissue for unknown reasons. LEMS occurs because autoantibodies damage the “voltage-gated calcium channels (VGCC)” on the motor nerve membrane at the neuromuscular junction. These channels normally conduct calcium into the nerve resulting in release of a chemical known as acetylcholine. Acetylcholine helps in the communication between nerve cells and muscles and is one of a group of chemicals known as neurotransmitters, which help to transmit nerve impulses. The autoantibodies attack the VGCC resulting in less acetylcholine release.
In patients who have LEMS associated with cancer, the immune mediated response is initiated because VGCC are present on the surface of cancer cells and the immune system triggers the production of antibodies to fight off cancer cells. The idea is that autoantibodies created against the VGCC on the small cell lung cancer mistakenly attack the VGCC on the nerve membrane instead. One of the major risk factors for SCLC is smoking, and in patients who have LEMS associated with cancer, a long history of smoking is also a major contributing factor.
In people who have LEMS not associated with cancer, genetic associations have been made with human leukocyte antigen (HLA) genotypes. HLA are proteins also present on the cell surface, and their function is to regulate the human immune system. However, it is unknown what causes these proteins to go awry array and trigger autoantibody production.
The estimated worldwide prevalence of LEMS is about 2.8 per million, making it a rare disease. There are approximately 400 known cases of LEMS in the United States. When LEMS is associated with SCLC, the patients tend to be older and are more likely to be men than women. The average age of onset of SCLC is around 60 years of age. Approximately 3% of SCLC patients develop LEMS, but clinical symptoms of LEMS usually precede the SCLC diagnosis (sometimes by many years). When LEMS is not related to cancer, the syndrome may occur at any age, and the typical onset is about 35 years of age. LEMS is extremely rare in the pediatric population, and there have only been 11 affected children reported in literature.
Diagnosis of LEMS is based on clinical symptoms and signs. A few diagnostic testing methods are available to help diagnose LEMS. Electrophysiological studies, are done to measure muscle response and muscle strength. Repetitive nerve stimulation measures the electrical activity of the muscle upon stimulation. Antibody testing is done in order to identify the presence of anti-VGCC antibodies.
Electromyography results usually show a decrease in compound motor action potential (CMAP). Repetitive nerve stimulation initially shows a small amount of electrical activity in the muscle. After high frequency repetitive stimulation or exercise, there is increased activity in the muscle.
Anti-VGCC antibodies are detectable in approximately 85% of LEMS patients and when detected they are highly specific for the condition. This is because anti- VGCC antibodies are found in LEMS with SCLC and in LEMS without cancer association.
Screening for SCLC is a very important part of the diagnostic workup for LEMS. A chest CT (and sometimes FDG-PET) scan will usually form the basis of this screening. Depending on the risk profile, a negative initial screen will be repeated at suitable time intervals. A recently discovered tumor marker antibody directed against SOX, which is found in 65% of SCLC LEMS patients as opposed to only 5% of non-tumor LEMS patients, may help guide clinical practice in the future.
Treatment of LEMS may vary depending upon the presence of associated cancer. If cancer is present, treatment first involves treatment directed at the cancer, this alone may result in relief of LEMS symptoms.
There is no cure for LEMS and treatment usually involves improving quality of life. Therefore, symptomatic treatment is the focus in the management of LEMS. The FDA has recently approved a new drug for the symptomatic relief of symptoms associated with muscle weakness called Firdapse (amifampridine). It is a potassium channel blocker that works by increasing the release of acytelcholine. At this time, it is the only drug approved for the indication of LEMS. The medication has shown to have significant benefits such as improving muscle strength and CMAP. In addition, it is a well-tolerated medication.
If Firdapse alone does not improve symptoms, there are additional options that can be added in case of symptom progression. Menstinon is indicated for the treatment of MG, but is often used in combination with Firdapse to treat symptoms of autonomic dysfunction (dry mouth, dry eyes, constipation, impotence and, decreased sweating). In MG, Menstinon improves muscle strength, but in LEMS, it has only shown to improve symptoms of autonomic dysfunction.
Drugs that suppress the activity of the immune system (immunosuppressive drugs) are used in LEMS patients with more severe symptoms, e.g. prednisone (alone or in conjunction with azathioprine or cyclosporin). In some patients, a course of high dose immunoglobulins may prevent further disease progression.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Some current clinical trials also are posted on the following page on the NORD website:
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Jayarangaiah A, Theethat KP. Lambert Eaton myasthenic syndrome. In: StatPearls. Treasure Island(FL):StatPearls Publishing; 2018.
Parsons KT. Lambert-Eaton Myasthenic Syndrome. In: NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:621.
Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1496-97.
Fauci AS, et al., eds. Harrison’s Principles of Internal Medicine, 14th Ed. New York, NY: McGraw-Hill, Inc; 1998:2470.
Bennett JC, Plum F., eds. Cecil Textbook of Medicine. 20th ed. Philadelphia, PA: W.B. Saunders Co; 1996:1018.
Schoser B, Eymard B, DattJ, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J neurol. 2017;264(9):1854-1863.
Abenroth DC, Smith AG, Greenlee JE, Austin SD, Clardy SL. Lambert-Eaton myasthenic Syndrome: epidemiology and therapeutic response in the national veterens affairs population. Muscle and Nerve. 2017;56(3):421-426.
Ha JC, Richmound DP. Myasthenia gravis and related disorders: pathology and molecular pathogenesis. Biochim Biophys Acta. 2015; 1852(4):651-657.
Mantegazza R, Meisel A, Sieb JP, et al. The European LEMS registry: baseline demographics and treatment approaches. Neuro Ther. 2015;2015(4):105-124.
Morgan-Followell B, de los Reyes E. Child neurology: diagnosis of Lambert-Eaton myasthenic syndrome in children. Neurology. 2013;80:220-222.
Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis and therapy. Autoimmune Dis. 2011;201:973-808.
Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;(2):CD003279.
Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Current Medical Research and Opinion. 2010;26(6):1363-1375.
Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-107.
Titulaer MJ, Klooster R, Potman M et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27(26):4260-7.
Van Petegem F, Clark KA, Chatelain FC, Minor DL Jr. Structure of complex between a voltage-gated calcium channel beta-subunit and an alpha-subunit. Nature. 2004;429:671-5.
Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367-75.
Newsom-Davis J. Lambert-Eaton myasthenic syndrome. Rev Neurol. 2004;160:177-80.
Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003;1998:500-9.
Tim RW, et al. Lambert-Eaton myasthenic syndrome: Electrodiagnostic findings and response to treatment. Neurology. 2000; 54:2176-78.
Takamori M, Komai K, Iwasa K. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. J Med Sci. 2000; 319(4):204-08.
Deneviratne U, de Silva R. Lambert-Eaton myasthenic syndrome. Postgrad Med J. 1999; 75(887):516-20.
Kumakura S, et al. Bone marrow necrosis and the Lambert-Eaton syndrome associated with interferon alfa treatment. New Eng J Med 1998; 338:199-200.
O’Suilleabhain P, et al. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology. 1998; 50:88-93.
Katz JS et al. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1998; 50:470-75.
Verschuuren JJ et al. Antibodies against the calcium chanel beta-subunit in Lambert-Eaton myasthenic syndrome. Neurology. 1998; 50:475-79.
McEvoy KM. 3,4 diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. New Eng J Med 1989; 321:1567-71.
Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Calcium Channel, Voltage-Dependent, BETA-2 Subunit; CACNB2. Entry No: 600003. Last Edited 11/06/2014. Available at: http://omim.org/entry/600003 Accessed January 29, 2019.
Stickler DE. Lambert-Eaton Myasthenic Syndrome (LEMS). Medscape. http://emedicine.medscape.com/article/1170810-overview Updated: Dec 26, 2018. Accessed January 29, 2019.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100